MB Research offers a novel in vitro sensitization screening tests that can be used to identify dermal sensitizers.
Allergic Contact Dermatitis (ACD), the clinical manifestation of contact sensitization, can be caused by dermal exposure to pharmaceuticals, industrial chemicals, consumer products and cosmetics. This is a serious health concern to consumers and governmental regulatory agencies alike. Contact dermatitis can cause physical, emotional and occupational issues for those affected, with an estimated annual cost of $1 Billion. Substances are routinely tested for sensitization potential in laboratory animal studies, such as the Local Lymph Node Assay.
We have developed an integrated testing strategy of in vitro assays that closely parallels the adverse outcome pathway as a skin sensitizer/allergen reacts to human skin.
The In Vitro Sensitization Assay (IVSA) is a keratinocyte activation test. IVSA uses an ELISA method to measure IL-18 release from a topically treated reconstructed 3D human keratinocyte tissue model.
The Human Cell Line Activation Test (h-CLAT) is a dendritic cell activation test. The h-CLAT uses flow cytometry to measure CD86 and CD54 expression on treated THP-1 cells in culture.
The Direct Peptide Reactivity Assay (DPRA) is an in chemico method used to predict epidermal protein binding. Binding of epidermal proteins is the molecular initiating event on the AOP. The DPRA uses HPLC to measure the depletion of synthetic peptides in solution following exposure to test chemicals.